Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monoprost vs Xalatan in Glaucoma and Ocular Hypertension
NCT04743622Phase 4Completed
- Sponsor
- CHA University
- Start
- Apr 2019
- Primary completion
- Jun 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of latanoprost in Glaucoma and ocular hypertension, sponsored by CHA University. Primary endpoints: Corneal staining at 12 weeks and Conjunctival staining at 12 weeks. Started Apr 2019; status: completed.
02
Drugs
latanoprost
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT04743622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04743622.